Clinical Trial

The Optimising Isolation, Quarantine and Distancing Study for COVID-19

Study acronym: Optimise
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The Australian government swift interventions and actions early to the COVID 19 epidemic included enforced quarantine, isolation, varying degrees of social and physical distancing measures, travel restrictions, community level testing and enhanced contact tracing models which effected the trajectory of the epidemic impact. While the search for effective therapeutics and vaccines continues, it is important to understand how to effectively implement and optimise the current public health interventions available; application of traditional contact tracing , contributions of new contact tracing mobile phone applications, community level testing and use of specific fit for purpose diagnostic tests; to screen, detect and provide evidence of infection clearance. While the suppression measures have been effective on disease transmission rates, it has had economic, social and non COVID-19 health costs impacts. As community restrictions change it will be important to monitor and evaluate the effectiveness of these key interventions. This is a longitudinal study that will follow the experience and behaviors of 2 key risk populations impacted by COVID-19 transmission containment measures.
Trial Details
NCT Number NCT07337382
Lead Sponsor Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Collaborators: The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Swinburne University of Technology, La Trobe University, Monash University, SNA Toolbox, Centre for Culture, Ethnicity & Health, Macquarie Group Foundation, Victorian State Government
Conditions COVID19
Enrollment 1,000 participants
Start Date 2020-09-30
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-13